

# Double Aortic and Mitral Valve-in-Valve Implantation

## Technical tips and tricks

*Jian (James) Ye, MD FRCPC*

**Clinical Professor of Surgery**

**St. Paul's Hospital, University of British Columbia**

AP VALVES 2018, Seoul



Centre for  
Heart Valve Innovation  
St. Paul's Hospital, Vancouver



**HEART CENTRE**  
AT ST. PAUL'S HOSPITAL


# Disclosure

**Consultant:**


**Edwards Lifesciences  
JC Medical Inc.**

# **Double aortic and mitral valve-in-valve case**

# Transapical Approach





**Aortic VinV**



**Mitral VinV**

# Double Aortic and Mitral Valve-in-Valve Implantation



# Tips and Tricks

The background is a solid blue color. A thin, light blue curved line starts from the top left and arcs across the top towards the right. On the right side, there is a larger, semi-transparent blue shape that appears to be a stylized arrow or a decorative element pointing towards the center.

# Confirming True Failure of Bioprosthesis

- **TEE is necessary prior to consideration of VinV:**
  - **Small size of bioprosthesis**
  - **Obese patient**
  - **Moderately elevated pressure gradient with a small aortic valve area**
  - **Rapid progression of stenosis**
  - **Early failure**
  - **Endocarditis?**



# **Understanding unique futures of surgical valves**



# Unique design of each surgical valve



CE Perimount  
Magna



CE Perimount  
Magna Ease



Sorin Mitroflow



Trifecta  
(St. Jude Medical)



Medtronic  
Hancock II



Medtronic Mosaic



CE Porcine SAV



Biocor



Edwards Prima  
Plus



Medtronic  
Freestyle




St. Jude Toronto  
SPV




Sorin Freedom


# Visibility of valves on fluoroscopy




**Magna Ease**




**Mosaic**



**Trifecta**






**Mitroflow**




**Epic**

# True Internal Diameter



# Marked valve size

(Magna pericardial tissue valve)



- A** Stent diameter (wireform)
- B** Tissue annulus diameter
- C** External sewing ring diameter
- D** Anterior effective profile


Size	25 mm	27 mm	29 mm	31 mm	33 mm
<b>A</b>	25	27	29	31	31
<b>B</b>	28	29.5	31.5	33.5	33.5
<b>C</b>	36	38	40	42	44
<b>D</b>	7	7.5	8	8.5	8.5



# Marked valve size (Mosaic tissue valve)


## Mosaic Aortic Bioprosthesis Model 305

Catalog Number	Valve Size (Stent O.D.†) (A)	Orifice Diameter (Stent I.D.) (B)	Suture Ring Diameter (C)	Valve Height (D)	Aortic Protrusion (E)
	(±0.5 mm)	(±0.5 mm)	(±1 mm)	(±0.5 mm)	(±0.5 mm)
30501901	19	17.5	25.0	13.5	11.0
30502101	21	18.5	27.0	15.0	12.0
30502301	23	20.5	30.0	16.0	13.5
30502501	25	22.5	33.0	17.5	15.0
30502701	27	24.0	36.0	18.5	15.5
30502901	29	26.0	39.0	20.0	16.0





## Mosaic Mitral Bioprosthesis Model 310

Catalog Number	Valve Size (Stent O.D.†) (A)	Orifice Diameter (Stent I.D.) (B)	Suture Ring Diameter (C)	Valve Height (D)	Ventricular Protrusion (E)
	(±0.5 mm)	(±0.5 mm)	(±1 mm)	(±0.5 mm)	(±0.5 mm)
31002501	25	22.5	33.0	18.0	13.5
31002701	27	24.0	35.0	19.0	14.0
31002901	29	26.0	38.0	20.5	15.5
31003101	31	28.0	41.0	22.0	17.0
31003301	33	30.0	43.0	23.0	17.5









† Equivalent to annulus diameter

# Is CT measurement of ID reliable?





# True Internal Diameter





# Valve in Valve Apps






Free to download





# **Risk factors for coronary obstruction**

- **Anatomic factors:**
  - Narrow aortic root**
  - Narrow and low STJ**
  - Low coronary ostium**
- **Unfavorable designs of tissue valves:**
  - High profile of tissue valves**
  - Outside-mounted tissue valve**
- **Tilted surgical valve**
- **Technical factors:**
  - Too much oversizing**
  - Selection of PHVs**

# Aortic Root



# VCT to assess risk of coronary obstruction




# Design of bioprotheses

## Profile



# Design of bioprotheses


## Outside vs inside mounted leaflets







# Left Main Occlusion

Many risk factors in this case







# Left Main Obstruction

less risk factors





# Selecting an appropriate THV in patients with high risk of LM obstruction





# Potential Malposition of aortic THV due to mitral tissue valve



# **Approach in patients with aortic and mitral valve-in-valve**

**Transapical for both aortic and mitral VinV**

**VS**

**Transeptal for mitral VinV + Transfemoral for aortic VinV**

# Determining THV size

- **True ID of surgical stented valve**
- **CT measurement of annulus size of surgical stentless valve**
- **VCT estimated distance to each coronary ostium**
- **STJ height and size**
- **AS vs AI of bioprosthesis, which may influence valve selection**
- **Neo-LVOT size – mitral valve-in-valve**


# Small surgical valve is an independent risk factor for reduced long-term survival

**TABLE 4** Factors Influencing the Survival of Aortic Valvular Patients (n = 42)

	Univariate Model		Multivariate Model	
	Hazard Ratio (95% CI)	p Value	Hazard Ratio (95% CI)	p Value
Female	2.485 (0.614-10.07)	0.202		
PVD	2.752 (0.747-10.14)	0.128		
PASP $\geq$ 60 mm Hg	2.906 (0.692-12.21)	0.145		
LVEF <50%	1.742 (0.489-6.207)	0.392	2.945 (1.472-25.99)	0.049
CABG $\pm$ CAD	0.784 (0.177-3.475)	0.749		
Creatinine 100-149 mmol/l	0.925 (0.127-6.749)	0.938		
Creatinine $\geq$ 150 mmol/l	2.126 (0.428-10.57)	0.357		
DM	2.601 (0.639-10.59)	0.182	4.779 (0.741-11.71)	0.125
CVA	0.773 (0.995-6.304)	0.810		
Surgical valve size <23 mm	3.420 (0.951-12.30)	0.060	6.186 (1.001-22.82)	0.013

# Global VinV Registry


**FIGURE 6** Rate of High Transvalvular Gradients Following Aortic Valve-in-Valve Procedures



# Global VinV Registry

Severe PPM = Effective  
orifice area  $<0.65 \text{ cm}^2/\text{m}^2$

Dvir D. EuroPCR, May 21, 2015



# Select an appropriate THV

- **ID > 20mm:** most types of THVs are OK
- **ID < 20mm:** Supra-annularly mounted THVs, such as Evolut R
- **ID < 20mm:** Evolut R, S3, or other THV with breaking surgical basal ring



# Potential for fracture of basal ring

Table 1: Combined Results of Bioprosthetic Valve Fracture Bench Testing



Manufacturer/ Brand	Valve Size	Bard TRU Balloon Fracture/Pressure	Bard Atlas Gold** Fracture/Pressure	Appearance After Fracture
St. Jude Triecta	19 mm 21 mm	NO NO	NO NO	
St. Jude Biocor Epic	21 mm	YES/ 8 atm	NOT TESTED	
Medtronic Mosaic	19 mm 21 mm	YES/ 10 atm YES/ 10 atm	YES/ 10 atm YES/ 8 atm	
Medtronic Hancock II	21 mm	NO	NOT TESTED	
Sorin Mitroflow	19 mm 21 mm	YES/ 12 atm YES/ 12 atm	NOT TESTED YES/ 10 atm	
Edwards MagnaEase	19 mm 21 mm	YES/ 18 atm YES/ 18 atm	YES/ 19 atm YES/ 21 atm	
Edwards Magna	19 mm 21 mm	YES/ 24 atm YES/ 24 atm	NOT TESTED	




Ballons sized 1 mm larger than valve size. The Medtronic Mosaic and Sorin Mitroflow have an integrated Thoracic, their appearance after fracture is similar to that of the Hancock II. Johanson, et al., 2017; Allen, et al., 2017; \*\*these data obtained from Johanson et al.




# Fracture of surgical basal ring



# Fracture of surgical basal ring



Pre-fracture




Post-fracture

# Mitral V-in-V in double aortic and mitral V-in-V

- Usually, no size issue
- Slightly more oversizing
- Ruling out LA thrombosis
- LVOT assessment


# Predicting factors for LVOT obstruction



**Aortomitral  
angulation**



**LV size**




**Ventricular  
septum**





**Profile of surgical  
valve**






# TEE to assess LVOT



# CT to assess risk of LVOT obstruction





# Optimal Position of THV



2-3 mm

# Slightly Oversizing

Outflow side > inflow side or a visible waist





# Clinical Experience in double aortic and mitral VinV

- **10 year clinical experience at our center**
- **CT assessment is essential**
- **Apical approach is excellent, performing aortic v-in-v first**
- **Extremely low mortality and morbidity**
- **Excellent clinical outcomes**
- **Become a favorable therapy for failed double aortic and mitral tissue valves at our center**
- **Anticoagulation with ASA + Warfarin**

THANKS!